2-氟-3-(羟基甲基)苯甲酸 | 481075-37-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-3-(羟基甲基)苯甲酸
• 中文别名: 2-氟-3-(羟甲基)苯甲酸
• 英文名称: 2-fluoro-3-(hydroxymethyl)benzoic acid
• CAS: 481075-37-0
• 化学式: C₈H₇FO₃
• 分子量: 170.14
• InChiKey: VZUWHOMAXWKXOF-UHFFFAOYSA-N

物化性质

• 沸点：
  346.6±32.0 °C(Predicted)
• 密度：
  1.417±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  2-氟-3-(羟基甲基)苯甲酸 在 氯化亚砜 作用下， 以 苯 为溶剂， 生成 3-(Chloromethyl)-2-fluorobenzoic acid
  参考文献：
  名称：

  Design, synthesis and identification of novel colchicine-derived immunosuppressant

  摘要：

  Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.054
• 作为产物：
  描述：

  2-fluoro-isophthalic acid dimethyl ester 在 N-甲基吗啉 、 sodium tetrahydroborate 、 水 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 86.5h， 生成 2-氟-3-(羟基甲基)苯甲酸
  参考文献：
  名称：

  METHOD FOR PREPARING TRICYCLIC DERIVATIVES

  摘要：

  本发明涉及一种制备三环衍生物的方法，更具体地，涉及一种制备高产率和纯度的三环衍生物中间体的方法，该方法包括：通过酯化和取代2-氟异苯二甲酸化合物引入一个羟基；引入一个哌啶基团；通过还原反应引入一个羟基；然后水解所得化合物，并且涉及使用该中间体制备三环衍生物的方法。根据本发明的方法，通过使用重新结晶而不是典型方法中的柱层析，可以提供高产率和经济可行性以及高纯度和收率的三环衍生物和其中间体。此外，本发明的方法可以用于工业大规模生产，因为使用的硼氢化钠或铝锂氢化物具有低火灾风险，而不像使用锂硼氢化物的典型方法那样由于火灾风险高而不适用于工业应用。

  公开号：

  US20120101296A1

文献信息

• ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS
  申请人：Controlled Chemicals, Inc.

  公开号：US20150175540A1

  公开（公告）日：2015-06-25

  Compounds having an isoindolin-1-one backbone of Formula (I) are disclosed which have utility in treating and/or preventing microbial infections, tumor growth, metastasis and other macrophage migration inhibitory factor (MIF)-modulated pathological conditions. Pharmaceutical compositions and methods and use of compounds of Formula (I) are also disclosed.

  公开了具有式(I)的异吲哚啉-1-酮骨架的化合物，其在治疗和/或预防微生物感染、肿瘤生长、转移以及其他巨噬细胞迁移抑制因子（MIF）调节的病理条件方面具有用途。还公开了式(I)化合物的药物组合物、方法和用途。
• [EN] MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES<br/>[FR] INHIBITEURS MACROCYCLIQUES DE PEPTIDYLARGININE DÉIMINASES
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222353A1

  公开（公告）日：2021-11-04

  The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

  本公开涉及用于治疗与肽精氨酸脱亚氨酶（PADs）相关的疾病的新化合物，例如肽精氨酸脱亚氨酶类型4（PAD4）。本公开还涉及用于制备这些化合物的过程和中间体，使用这些化合物的方法以及包含所述化合物的药物组合物。
• [EN] TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES TRICYCLIQUES OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES DERIVES, LEURS PREPARATIONS ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：JE IL PHARMACEUTICAL CO LTD

  公开号：WO2004113281A1

  公开（公告）日：2004-12-29

  The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.

  本发明涉及三环衍生物或其药用盐，其制备以及含有它们的药物组合物。更准确地说，本发明涉及三环衍生物作为秋水仙碱衍生物，其药用盐，其制备以及含有它们的药物组合物。本发明的三环衍生物对癌细胞系表现出非常强大的细胞毒性，但比秋水仙碱或紫杉醇毒性要小得多，经动物毒性试验证实。本发明的三环衍生物还可以减小肿瘤的体积和重量，并且在HUVEC细胞中具有强大的抑制血管生成活性。因此，本发明的三环衍生物可以有效地用作抗癌剂、抗增殖剂和血管生成抑制剂。
• Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
  申请人：Kim Myung-Hwa

  公开号：US20070179143A1

  公开（公告）日：2007-08-02

  The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.

  本发明涉及三环衍生物或其药学上可接受的盐、它们的制备方法以及含有它们的制药组合物。更具体地说，本发明涉及三环衍生物作为秋水仙素衍生物，药学上可接受的盐、它们的制备方法以及含有它们的制药组合物。本发明的三环衍生物对癌细胞株表现出非常强大的细胞毒性，但毒性比秋水仙素或紫杉醇要小得多，经动物毒性测试证实。本发明的三环衍生物还可以减少肿瘤的体积和重量，并在HUVEC细胞中表现出强大的抑制血管生成的活性。因此，本发明的三环衍生物可以有效地用作抗癌剂、抗增殖剂和抑制血管生成剂。
• ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Tong Youzhi

  公开号：US20120172406A1

  公开（公告）日：2012-07-05

  The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.

  本发明涉及新型取代硫代咪唑啉酮化合物及包含该类化合物的制药组合物，用于治疗与雄激素受体相关的疾病或疾病，例如前列腺癌、良性前列腺增生、男性脱发、肌肉萎缩、痤疮和多毛症。